Trial reportPloS one2018
Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.
Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00131677 (Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antiretroviral Concentration in Hair as a Measure for Antiretroviral Medication Adherence: A Systematic Review of Global Literature.AIDS and behavior · 2020Pooled it
- Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.Journal of the International AIDS Society · 2020Trial
- Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study.BMC women's health · 2023Article
- Article
- Agreement Between Measures of Adherence to Isoniazid Preventive Therapy Among People With HIV in Uganda.Open forum infectious diseases · 2022Article
- Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.Drug testing and analysis · 2021Article
- LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence.Molecules (Basel, Switzerland) · 2020Article
- Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.Current HIV/AIDS reports · 2020Review
- Influence of hair treatments on detection of antiretrovirals by mass spectrometry imaging.The Analyst · 2020Article
- Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin.Medicine · 2020Observational
- Comparing self-reported medication adherence measures with hair antiretroviral concentration among people living with HIV in Guangxi, China.AIDS research and therapy · 2020Article
- A Promising PrEP Navigation Intervention for Transgender Women and Men Who Have Sex with Men Experiencing Multiple Syndemic Health Disparities.Journal of community health · 2019Article
- Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring.Analytical chemistry · 2019Article
- Measuring Adherence to Antiretroviral Therapy via Hair Concentrations in India.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Preexposure Prophylaxis Monitoring in New York City: A Public Health Approach.American journal of public health · 2018Article
- Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.Rapid communications in mass spectrometry : RCM · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Sanjiv M BaxiDepartment of Medicine, University of California, San Francisco, California, United States of America.ORCID 0000-0002-2282-6140
Eric VittinghoffDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, United States of America.
Peter BacchettiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, United States of America.
Yong HuangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.
Kata ChillagDivision of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Atlanta, Georgia, United States of America.
Ryan WiegandDivision of Parasitic Diseases and Malaria, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Peter L AndersonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, United States of America.
Robert GrantDepartment of Medicine, University of California, San Francisco, California, United States of America.
Ruth M GreenblattDepartment of Medicine, University of California, San Francisco, California, United States of America.
Susan BuchbinderDepartment of Medicine, University of California, San Francisco, California, United States of America.
Monica GandhiDepartment of Medicine, University of California, San Francisco, California, United States of America.
Albert Y LiuDepartment of Medicine, University of California, San Francisco, California, United States of America.
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MWOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6MTRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3MChemoprophylaxis and HIV-Host InteractionsR01AI062333 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2004 to 2011
$6.2MPlugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6MCellular pharmacology of tenofovir and emtricitabine for HIV prophylaxisU01AI084735 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2009 to 2012
$4.2M“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2MNCATS NIH HHS UL1 TR000004NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI062333NIAID NIH HHS R01 AI098472NIAID NIH HHS R37 AI098472NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI084735NIMH NIH HHS T32 MH019105
Abstract
CLINICAL
trial registrationClinical Trials.gov NCT00131677.
Indexed as
Anti-HIV AgentsPre-Exposure ProphylaxisTenofovirHumansPlacebosUnited StatesAnti-HIV AgentsPlacebosTenofovir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
NCT00131677ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.